Blog

New Research Funding for LUNIRI
2018-08-21

Steffen Frese, the founder of LUNIRI, received new research funding from the German Research Foundation. http://gepris.dfg.de/gepris/projekt/317392477?language=en Research will be conducted at the German Rheumatism Research Centre in Berlin, Germany.&nb ... Read More

Berlin Marathon 2017
Running for lupus. Running for the new treatment.     2017-09-27

LUNIRI in the News
Lupus Nephritis and Irinotecan at LUPUSNEWSTODAY.COM     2016-11-30

http://lupusnewstoday.com/2016/11/11/irinotecan-topo-1-blocker-seen-as-potential-lupus-specific-treatment

Neue Ergebnisse aus der Forschung veröffentlich in Arthritis Research & Therapy
Wir konnten zeigen, dass Irinotecan in einem zweiten Model von spontaner Lupuserkrankung sowohl die Nieren- als auch die Hautbeteiligung effektiv unterdrückt.     2016-10-25

Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan. Arthritis Res Ther. 2016 Oct 22; 18(1):243

New scientific data published in Arthritis Research & Therapy
Irinotecan efficiently suppressed both lupus nephritis and skin lesions in a second and genetically different model of spontaneous SLE     2016-10-25

Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan. Arthritis Res Ther. 2016 Oct 22; 18(1):243

Cancelation of credit card payment
2016-05-27

Due to the absence of donations for LUNIRI in the context of monthly operating costs, transfer of donation by credit card will be canceled from 1st of June 2016. We deeply regret this development.

More Blog Entries

New experimental findings of LUNIRI were published in the journal Arthritis and Rheumatology

The topoisomerase I inhibitor irinotecan and the tyrosyl-DNA phosphodiesterase 1 inhibitor furamidine synergistically suppress murine lupus nephritis     2015-03-18

In the current publication we show that the topoisomerase I (topo I) inhibitor irinotecan and the tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitor furamidine in combination efficiently suppress lupus nephritis. While inhibitors of topo I stabilize the complex of topo I and DNA, the enzyme TDP1 releases topo I from the stalled complex. One previously known consequence of topo I inhibition is the prevention of DNA relaxation; this effect can be reverted by addition of TDP1. We demonstrated that these effects correlate with the binding of anti-dsDNA antibodies which are believed to be the main pathogen in systemic lupus erythematosus (SLE). We conclude from these data that DNA relaxation is crucial in the development of SLE and furthermore, changes in DNA relaxation by topo I and TDP1 inhibitors can be applied as entire new targeted therapy for this disease (Keil A. et al. Arthritis Rheumatol. 2015 Mar 16. doi: 10.1002/art.39119).

Congratulations to Andreas for his first publication as first author! Thanks to the team!


Categories: English